Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03683680 · ClinicalTrials.gov registry record · NA
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
A NA study of Mesothelioma, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT03683680: Recruiting NA study of Mesothelioma, sponsored by Dana-Farber Cancer Institute.
NCT03683680 is a NA study of Mesothelioma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 240 participants, above the 193-participant average among 46 other Mesothelioma trials with a reported enrollment target (24% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03683680, a NA study of Mesothelioma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.
Primary Outcome
The primary objective is to utilize a novel prognostic algorithm to predict the outcome of MPM patients. This algorithm includes 4 different tests: molecular, radiological, and blood based. It will be performed on 240 prospectively-collected samples. A score of 0-4 will be assigned to each patient and the data will be analyzed by a statistician
Conditions Studied
Interventions
- OTHER MPT Test
- OTHER CLDN15/VIM Test
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2030-10-01 |
| Phase | NA |
What NCT03683680 shows while recruiting
NCT03683680 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 193-participant average among 46 other Mesothelioma trials with a reported enrollment target (24% higher).
The record links to 1 condition, with Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which MPT Test is the first listed.
NCT03683680 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03683680 about?
NCT03683680 is a clinical study titled "Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers". This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.
What is the current status of trial NCT03683680?
This trial is currently recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2018-10-31. Estimated completion is 2030-10-01.
What conditions does trial NCT03683680 study?
This clinical trial studies the following conditions: Mesothelioma.
What interventions are being tested in trial NCT03683680?
The interventions under investigation include: MPT Test (OTHER), CLDN15/VIM Test (OTHER).
Who is sponsoring clinical trial NCT03683680?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03683680 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03683680's enrollment target sits among peer trials
240 13th of 46 higher than 33 of 46 other Mesothelioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mesothelioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
RECRUITING · NA
-
A Study of Sacituzumab Govitecan in People With Mesothelioma
RECRUITING · Phase 2
-
Olaparib in Patients With HRD Malignant Mesothelioma
RECRUITING · Phase 2
-
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
RECRUITING
-
Rapid Autopsy and Procurement of Cancer Tissue
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI